Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cizolirtine
- Development stage
- Phase 3
- Lead developer
- Esteve
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cizolirtine is a small molecule pyrazole derivative originally developed by Esteve Pharmaceuticals for the treatment of various pain conditions and urinary incontinence secondary to overactive bladder. Its mechanism of action involves the modulation of neuropeptide release, specifically inhibiting the presynaptic release of substance P (SP) and calcitonin gene-related peptide (CGRP) at the spinal cord level. This inhibitory effect is mediated through an alpha-2 adrenoceptor-dependent pathway. Clinical development reached Phase II and Phase III for indications including neuropathic pain, renal colic, cancer pain, and diabetic neuropathy, as well as overactive bladder. However, the global research and development for cizolirtine has been discontinued.
- Other names
- cizolirtine citrate
02
Targets
ADRA2A (α2A)CGRP (Calcitonin gene-related peptide)SP (Substance P)
Beyond the preview
Go deeper on cizolirtine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cizolirtine.